Synthesis and antimicrobial Evaluation of Novel 2'-aryl-4-aryl-2,4'-Bisthiazole and 2'-aryl-4-Pyridyl-2,4'-Bisthiazole Derivatives as Potential Antibacterial Agents

References

• D. van Duin, and D. L. Paterson, “Multidrug-Resistant Bacteria in the Community: Trends and Lessons Learned,” Infectious Disease Clinics of North America 30, no. 2 (2016): 377–90. doi:10.1016/j.idc.2016.02.004
   PubMed Web of Science ®Google Scholar
• E. L. Berkow, and S. R. Lockhart, “Fluconazole Resistance in Candida Species: A Current Perspective,” Infection and Drug Resistance 10 (2017): 237–45. doi:10.2147/IDR.S118892
   PubMed Web of Science ®Google Scholar
• J. H. Powers, “Antimicrobial Drug Development-the past, the Present, and the Future,” Clinical Microbiology and Infection 10, no. 4 (2004): 23–31. doi:10.1111/j.1465-0691.2004.1007.x
   PubMedGoogle Scholar
• H. W. Boucher, G. H. Talbot, J. S. Bradley, J. E. Jr. Edwards, D. Gilbert, B. Rice, M. Scheld, B. Spellberg, and J. Bartlett, “Bad Bugs, No Drugs: no ESKAPE! an Update from the Infectious Diseases Society of America,” Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 48, no. 1 (2009): 1–12. doi:10.1086/595011
   PubMed Web of Science ®Google Scholar
• D. E. Brown, and D. G. Wright, “Antibacterial Drug Discovery in the Resistance Era,” Nature 529, no. 7586 (2016): 336–43. doi:10.1038/nature17042
   PubMed Web of Science ®Google Scholar
• R. Aminov, “History of Antimicrobial Drug Discovery: Major Classes and Health Impact,” Biochemical Pharmacology 133 (2017): 4–19. doi:10.1016/j.bcp.2016.10.001
   PubMed Web of Science ®Google Scholar
• N. D. Friedman, D. Levit, E. Taleb, G. Marcus, L. Michaeli, M. Broide, B. Mengesha, R. Zaidenstein, T. Lazarovitch, M. Dadon, et al, “Towards a Definition for Health Care-Associated Infection,” Open Forum Infect Dis 5, no. 6 (2018): 116–22.
   Web of Science ®Google Scholar
• P. Mohanty, S. Behera, R. Behura, L. Shubhadarshinee, P. Mohapatra, A. K. Barick, and B. R. Jali, “Antibacterial Activity of Thiazole and Its Derivatives: A Review,” Biointerface Research in Applied Chemistry 12, no. 2 (2022): 2171–95.
   Web of Science ®Google Scholar
• Isha Mishra, Raghav Mishra, Somdutt Mujwar, Phool Chandra, and Neetu Sachan, “A Retrospect on Antimicrobial Potential of Thiazole Scaffold,” Journal of Heterocyclic Chemistry 57, no. 6 (2020): 2304–29. doi:10.1002/jhet.3970
   Web of Science ®Google Scholar
• Y. K. Abhale, A. V. Sasane, A. P. Chavan, S. H. Shekh, K. K. Deshmukh, S. Bhansali, L. Nawale, D. Sarkar, and P. C. Mhaske, “Synthesis and Antimycobacterial Screening of New Thiazolyl-Oxazole Derivatives,” European Journal of Medicinal Chemistry. 132 (2017): 333–40. doi:10.1016/j.ejmech.2017.03.065
   PubMed Web of Science ®Google Scholar
• S. M. Jagadale, Y. K. Abhale, H. R. Pawar, A. Shinde, V. D. Bobade, A. P. Chavan, D. Sarkar, and P. C. Mhaske, “Synthesis of New Thiazole and Pyrazole Clubbed 1, 2, 3-Triazol Derivatives as Potential Antimycobacterial and Antibacterial Agents,” Polycyclic Aromatic Compounds 42, no. 6 (2022): 3216–37. doi:10.1080/10406638.2020.1857272
   Web of Science ®Google Scholar
• Y. Li, N. Sun, H. Ser, W. Long, Y. Li, C. Chen, B. Zheng, X. Huang, Z. Liu, and Y. Lu, “Antibacterial Activity Evaluation and Mode of Action Study of Novel Thiazole-Quinolinium Derivatives,” RSC Advances 10, no. 25 (2020): 15000–14. doi:10.1039/d0ra00691b
   PubMed Web of Science ®Google Scholar
• Y. K. Abhale, A. Shinde, K. K. Deshmukh, L. Nawale, D. Sarkar, and P. C. Mhaske, “Synthesis, Antitubercular and Antimicrobial Potential of Some New Thiazole Substituted Thiosemicarbazide Derivatives,” Medicinal Chemistry Research 26, no. 10 (2017): 2557–67. doi:10.1007/s00044-017-1955-1
   Web of Science ®Google Scholar
• Haroon Mohammad, Hassan E. Eldesouky, Tony Hazbun, Abdelrahman S. Mayhoub, and Mohamed N. Seleem, “Identification of a Phenylthiazole Small Molecule with Dual Antifungal and Antibiofilm Activity against Candida albicans and Candida auris,” Scientific Reports 9, no. 1 (2019): 18941. doi:10.1038/s41598-019-55379-1
   PubMedGoogle Scholar
• N. D. Gaikwad, S. V. Patil, and V. D. Bobade, “Synthesis and Biological Evaluation of Some Novel Thiazole Substituted Benzotriazole Derivatives,” Bioorganic & Medicinal Chemistry Letters 22, no. 10 (2012): 3449–54. doi:10.1016/j.bmcl.2012.03.094
   PubMed Web of Science ®Google Scholar
• M. Kumar, V. Kumar, V. Singh, and S. Thakral, “Synthesis, in Silico Studies and Biological Screening of (E)-2-(3-(Substitutedstyryl)-5-(Substitutedphenyl)-4, 5-Dihydropyrazol-1-yl) Benzo [d] Thiazole Derivatives as an anti-Oxidant, anti-Inflammatory and Antimicrobial Agents,” BMC Chemistry 16, no. 1 (2022): 1–19. doi:10.1186/s13065-022-00901-2
   PubMed Web of Science ®Google Scholar
• Ekaterina Pivovarova, Alina Climova, Marcin Świątkowski, Marek Staszewski, Krzysztof Walczyński, Marek Dziȩgielewski, Marta Bauer, Wojciech Kamysz, Anna Krześlak, Paweł Jóźwiak, et al, “Synthesis and Biological Evaluation of Thiazole-Based Derivatives with Potential against Breast Cancer and Antimicrobial Agents,” International Journal of Molecular Sciences 23, no. 17 (2022): 9844. doi:10.3390/ijms23179844
   PubMed Web of Science ®Google Scholar
• V. Kartsev, A. Geronikaki, A. Zubenko, A. Petrou, M. Ivanov, J. Glamočlija, M. Sokovic, L. Divaeva, A. Morkovnik, and A. Klimenko, “Synthesis and Antimicrobial Activity of New Heteroaryl (Aryl) Thiazole Derivatives Molecular Docking Studies,” Antibiotics 11, no. 10 (2022): 1337. doi:10.3390/antibiotics11101337
   Google Scholar
• (a) M. Ojika, Y. Suzuki, A. Tsukamoto, Y. Sakagami, R. Fudou, T. Yoshimura, and S. Yamanaka, “Cystothiazoles a and B, New Bithiazole-Type Antibiotics from the Myxobacterium Cystobacter fuscus,” The Journal of Antibiotics 51, no. 3 (1998): 275–81. doi:10.7164/antibiotics.51.275
   PubMed Web of Science ®Google Scholar
  (b) M. Ojika, Y. Suzuki, A. Tsukamoto, Y. Sakagami, R. Fudou, T. Yoshimura, and S. Yamanaka, “Cystothiazoles C-F, New Bithiazole-Type Antibiotics from the Myxobacterium Cystobacter fuscus,” The Journal of Antibiotics 51, no. 3 (1998): 275–81. doi:10.7164/antibiotics.51.275
   PubMed Web of Science ®Google Scholar
• (a) K. Gerzt, H. Irschik, H. Reichenbach, and W. Trowitzsch, “Myxothiazol, an Antibiotic from Myxococcusfulvus (Myxobacterales). I. Cultivation, Isolation, Physico-Chemical and Biological Properties,” Antibiot 33, no. 12 (1980): 1474–9.
   Google Scholar
  (b) W. Trowitzsch, G. Reifenstahl, V. Wray, and K. Gerth, “Myxothiazole, an Antibiotic from myxococcus fulvus (Myxobacterales) ii. structure Elucidation,” The Journal of Antibiotics 33, no. 12 (1980): 1480–90, and 33. doi:10.7164/antibiotics.33.1480
   PubMed Web of Science ®Google Scholar
  (c) W. Trowitzsch, G. Höfle, and W. S. Sheldrick, “The Stereochemistry of Myxothiazol,” Tetrahedron Letters. 22, no. 39 (1981): 3829–32. doi:10.1016/S0040-4039(01)91320-6
   Web of Science ®Google Scholar
  (d) J. M. Clough, “The Strobilurins, Oudemansins, and Myxothiazols, Fungicidal Derivatives of β-Methoxyacrylic Acid,” Natural Product Reports. 10 (1993): 565.
   PubMed Web of Science ®Google Scholar
• C. Araniciu, M. Palage, S. Oniga, A. Pirnau, P. Verite, and O. Oniga, “Synthesis and Characterization of Some Novel 5, 2-and 4, 2-Bisthiazoles Derivatives,” Rev. Chim. Buchar 64, no. 10 (2013): 1067–71.
   Web of Science ®Google Scholar
• C. Araniciu, L. Marutescu, S. Oniga, O. Oniga, M. C. Chifiriuc, and M. Palage, “Evaluation of the Antimicrobial and anti-Biofilm Activity of Some 4,2 and 5,2 Bisthiazoles Derivatives,” Digest Journal of Nanomaterials and Biostructures 9 (2014): 123–31.
   Web of Science ®Google Scholar
• T. Rozsa, M. Duma, L. Vlase, I. Ionut¸, A. Pîrnău, B. Tiperciuc, and O. Oniga, “Synthesis and Antimicrobial Evaluation of Some New 4,5′‐Bisthiazoles,” Journal of Heterocyclic Chemistry 52, no. 4 (2015): 999–1006. doi:10.1002/jhet.2054
   Web of Science ®Google Scholar
• L. Costea, O. Oniga, M. Ionescu, B. Tiperciuc, and D. Ghiran, “Synthesis and Antimicrobial Activity of Some New 2'-Arylideneamino-Dithiazoles and 2'-Arylidenehydrazino-5,4'- Dithiazole Compounds,” Farmacia (Bucharest, Romania) 53, no. 2 (2005): 67–75.
   Google Scholar
• M. C. Bagley, J. W. Dale, E. A. Merritt, and X. Xiong, “Thiopeptide Antibiotics,” Chemical Reviews 105, no. 2 (2005): 685–714. doi:10.1021/cr0300441
   PubMed Web of Science ®Google Scholar
• (a) J. Kettenring, L. Colombo, P. Ferrari, P. Tavecchia, M. Nebuloni, K. Vekey, G. G. Gallo, and E. Selva, “Antibiotic GE2270A: A Novel Inhibitor of Bacterial Protein Synthesis. II. Structure Elucidation,” The Journal of Antibiotics 44, no. 7 (1991): 702–15. doi:10.7164/antibiotics.44.702.
   PubMed Web of Science ®Google Scholar
  (b) K. I. Suzumura, T. Yokoi, M. Funatsu, K. Nagai, K. Tanaka, H. Zhang, and K. Suzuki, “YM266183 and YM-266184, Novel Thiopeptide Antibiotics Produced by Bacillus cereus Isolated from a Marine Sponge II. Structure Elucidation,” Journal of Antibiotics. 56 (2003): 129–34. doi:10.7164/antibiotics.44.702
   PubMed Web of Science ®Google Scholar
• R. Hughes, and C. Moody, “From Amino Acids to Heteroaromatics-Thiopeptide Antibiotics, Nature’s Heterocyclic Peptides,” Angewandte Chemie (International ed. in English) 46, no. 42 (2007): 7930–54. doi:10.1002/anie.200700728
   PubMed Web of Science ®Google Scholar
• P. Makam, and T. Kannan, “2-Aminothiazole Derivatives as Antimycobacterial Agents: Synthesis, Characterization, in Vitro and in Silicostudies,” European Journal of Medicinal Chemistry. 87 (2014): 643–56. doi:10.1016/j.ejmech.2014.09.086
   PubMed Web of Science ®Google Scholar
• A. Meissner, H. I. Boshoff, M. Vasan, B. P. Duckworth, C. E. Barry, and C. C. Aldrich, “Structure-Activity Relationships of 2-Aminothiazoles Effective against Mycobacterium tuberculosis,” Bioorganic & Medicinal Chemistry 21, no. 21 (2013): 6385–97. doi:10.1016/j.bmc.2013.08.048
   PubMed Web of Science ®Google Scholar
• M. Bonnet, J. Flanagan, D. Chan, E. Lai, P. Nguyen, A. Giaccia, and M. Hay, “SAR Studies of 4-Pyridyl Heterocyclic Anilines That Selectively Induce Autophagic Cell Death in Von Hippel-Lindau-Deficient Renal Cell Carcinoma Cells,” Bioorganic & Medicinal Chemistry 19, no. 11 (2011): 3347–56. doi:10.1016/j.bmc.2011.04.042
   PubMed Web of Science ®Google Scholar
• M. P. Hay, S. Turcotte, J. U. Flanagan, M. Bonnet, D. A. Chan, P. D. Sutphin, P. Nguyen, A. J. Giaccia, and W. A. Denny, “4-Pyridylanilinothiazoles That Selectively Target Von Hippel-Lindau Deficient Renal Cell Carcinoma Cells by Inducing Autophagic Cell Death,” Journal of Medicinal Chemistry 53, no. 2 (2010): 787–97. doi:10.1021/jm901457w
   PubMed Web of Science ®Google Scholar
• S. Oniga, M. Duma, O. Oniga, B. Tiperciuc, A. Pirnau, C. Araniciu, and M. Palage, “Synthesis of Some New 4-Methyl-2-(4-Pyridyl)-Thiazole-5-yl-Azoles as Potential Antimicrobial Agents,” Farmacia 63 (2015): 171–8.
   Web of Science ®Google Scholar
• W. Zhou, W. Tang, Z. Sun, Y. Li, Y. Dong, H. Pei, Y. Peng, J. Wang, T. Shao, Z. Jiang, et al, “Discovery and Optimization of n-Substituted 2-(4-Pyridinyl) Thiazolecarboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways,” Scientific Reports 6 (2016): 33434. doi:10.1038/srep33434
   PubMed Web of Science ®Google Scholar
• A. M. Alqahtani, and A. A. Bayazeed, “Synthesis and Antiproliferative Activity Studies of New Functionalized Pyridine Linked Thiazole Derivatives,” Arabian Journal of Chemistry 14, no. 1 (2021): 102914. doi:10.1016/j.arabjc.2020.11.020
   Web of Science ®Google Scholar
• Naime Funda Tay, Barkın Berk, Murat Duran, İsmail Kayagil, Leyla Yurttaş, Sevde Nur Biltekin Kaleli, Mustafa Yamaç, Ayşe Betül Karaduman, and Şeref Demirayak, “Synthesis, Antimicrobial Activity and Modeling Studies of Thiazoles Bearing Pyridyl and Triazolyl Scaffolds,” Zeitschrift Für Naturforschung C 77, no. 9-10 (2022): 429–46. doi:10.1515/znc-2022-0002
   PubMed Web of Science ®Google Scholar
• Naime Funda Tay, Murat Duran, İsmail Kayagil, Leyla Yurttaş, Gamze Göger, Fatih Göger, Fatih Demirci, and Şeref Demirayak, “Synthesis, Antimicrobial and Antioxidant Activities of Pyridyl Substituted Thiazolyl Triazole Derivatives,” Brazilian Journal of Pharmaceutical Sciences 58, e191026 (2022). doi:10.1590/s2175-97902022e191026
   Web of Science ®Google Scholar
• Y. K. Abhale, A. V. Sasane, A. P. Chavan, K. K. Deshmukh, S. S. Kotapalli, R. Ummanni, S. F. Sayyad, and P. C. Mhaske, “Synthesis and Biological Screening of 2-Aryl/Benzyl-2-Aryl-4-Methyl-4,5-Bithiazolyls as Possible anti-Tubercular and Antimicrobial Agents,” European Journal of Medicinal Chemistry 94, no. 2015 (2015): 340–7. doi:10.1016/j.ejmech.2015.03.016
   PubMedGoogle Scholar
• Y. K. Abhale, A. D. Shinde, K. K. Deshmukh, L. Nawale, D. Sarkar, P. B. Choudhari, S. S. Kumbhar, and P. C. Mhaske, “Synthesis, Antimycobacterial Screening and Molecular Docking Studies of 4-Aryl-4′-Methyl-2′-Aryl-2,5′-Bisthiazole Derivatives,” Medicinal Chemistry Research 26, no. 11 (2017): 2889–99. doi:10.1007/s00044-017-1988-5
   Web of Science ®Google Scholar
• NCCLS (National Committee for Clinical Laboratory Standards) method for dilution antimicrobial susceptibility tests of bacteria that grow aerobically,” P.A. Wayne 2002.
   Google Scholar
• NCCLS Approval Standard Document M2-A7, National Committee for Clinical Laboratory Standards, USA, Vilanova, PA, 2000.
   Google Scholar
• A. W. Bauer, W. M. Kirby, J. C. Sherris, and M. Turck, “Antibiotic Susceptibility Testing by a Standardized Single Disk Method,” American Journal of Clinical Pathology 45, no. 4 (1966): 493–6. doi:10.1093/ajcp/45.4_ts.493
   PubMed Web of Science ®Google Scholar
• S. H. Shelke, P. C. Mhaske, P. Hande, and V. D. Bobade, “Synthesis and Antimicrobial Activities of Novel Series of 1-((4-Methyl-2-Substituted Thiazol-5-yl)Methyleneamino)-2-Substituted Isothiourea Derivatives,” Phosphorus, Sulfur, and Silicon and the Related Elements 188, no. 9 (2013): 1262–70. doi:10.1080/10426507.2012.745542
   Web of Science ®Google Scholar